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Abstract
Antimicrobial resistance is a worldwide
threat and a problem with large clinical and
economic impact. Antimicrobial Stewardship
Programs are a solution to curb resistance
development. A problem of resistance is a
separation of actions and consequences,
financial and clinical. Such a separation
makes it difficult to create support among
stakeholders leading to a lack of sense of
responsibility. To counteract the resistance
development it is important to perform diag-
nostics and know how to interpret the results.
One should see diagnostics, therapy and
resistance as one single process. Within this
process all involved stakeholders need to
work together on a more institutional level.
We suggest therefore a solution: combining
diagnostics and therapy into one single finan-
cial product. Such a product should act as an
incentive to perform correct diagnostics. It
also makes it easier to cover the costs of an
antimicrobial stewardship program, which is
often overlooked. Finally, such a product
involves all stakeholders in the process and
does not lay the costs at one stakeholder and
the benefits somewhere else, solving the mis-
balance that is present nowadays.
Introduction
Antimicrobial resistance (AMR) is a
worldwide threat and problem. Loss of
effectiveness of antimicrobial therapy leads
to untreatable infections and is causing
already substantial loss of life.1,2 This is
expected to grow even more in the near
future. The economic impact is consequent-
ly also vast.2,3 A plan of action is thus need-
ed and this should focus on all aspects of
infection management as well as on public
awareness and involvement of pharmaceuti-
cal industries, but also veterinary and agri-
culture industries; it requires thus a world-
wide multi-sector response.2,4 With regards
to hospitals, Antimicrobial Stewardship
Programs (ASPs) are hailed as one the solu-
tions to tackle the development of AMR.5,6
These programs focus on improvement of
therapy by means of a set of diverse inter-
ventions. An important aspect is correct
diagnostics, without diagnostics physicians
are treating patients in fact blind. However,
implementation of these programs in
healthcare institutions is often a difficult
and long process.7 One of the reasons for
this difficult implementation might lie in the
fact that provided funds are insufficient. We
provide here an overview of the economic
aspects with regards to ASPs and possible
solutions from a financial point of view.
The misbalance of actions and 
consequences
One of the main problems of antimicro-
bial resistance is the fact that actions and
consequences are separated from each
other. Not just in time, but also in stakehold-
ers. This makes it more difficult to imple-
ment actions and create support. In hospi-
tals, clinical and financial effects from sub-
optimally antimicrobial use and the conse-
quent AMR often fall upon other depart-
ments or healthcare providers than the ini-
tiators of these problems (i.e. the pre-
scribers). This creates a lack of sense of
responsibility for these problems and is
translated into the fact that diagnostics are
often not performed according to guidelines
and also antimicrobial therapy is often sub-
optimally prescribed. The problems of these
actions occur often on the long(er) term, are
not directly visible, and others most likely
bear the consequences. These consequences
include patients with difficult to treat infec-
tions caused by resistant microorganisms. If
such an infection occurs, the respective
patient often already left the ward where
therapy was given initially and in some
cases even left the hospital. It therefore
might well be another hospital that has to
deal with this infected/colonized patient and
all the extra measures and costs such as iso-
lation and more expensive therapy. It also
makes difficult to convince healthcare
providers (or the prescribing department,
depending on the cost structure) to spend
money on the correct diagnostics and inter-
pretation of these diagnostics (e.g. via an
ASP), if it means that the benefits of those
expenditures lie with other parties. It is
therefore imperative to look at antimicro-
bial use in a more process-based manner,
taking into account all stakeholders within
the process. Firstly within one healthcare
center, however it is also important to col-
laborate with neighboring healthcare cen-
ters and define a healthcare region.8
Preferably, all costs and benefits are shared
among all stakeholders to remove the mis-
balance and create a more sustainable fund-
ing of both diagnostics and stewardship
measures. It is the task of microbiologists,
infectious disease specialists and pharma-
cists, to work together to achieve these
goals crossing borders between treating
specialties and between neighboring hospi-
tals and setting aside possible conflicting
issues. Only then, is it possible to create a
sustainable financial solution for the pre-
vention and management of antimicrobial
resistance.
The macroeconomic point-of-view
In May 2016 the final report of the
Review on Antimicrobial Resistance, led by
Jim O’Neill, was published.2 This is one of
the most important reports of the last couple
of years, mainly because it addressed the
problem from a worldwide, macroeconomic
point-of-view. Often, the bigger picture is
lost when focusing too much on single
patients or institutions. Especially with a
worldwide problem such as AMR and with
such large economic consequences, it is
important to look at the bigger picture. The
report once more confirmed the dire situa-
tion that the world faces with regards to
AMR. The financial impact will be huge,
with worldwide costs adding up to billions
per year, for a large part due to the loss of
workforce of people infected with resistant
and untreatable pathogens. Investments to
counteract AMR and subsequent problems
are expected to be dwarfed by the costs of
doing nothing.2
One of the main points addressed in the
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report, is the diagnostics, and more specifi-
cally the lack of appropriate and timely
diagnostics when antimicrobial therapy is
started. Before start of therapy, microbio-
logical diagnostics are normally required
and asked for in almost all guidelines.
However, in many cases, these diagnostics
are not performed or not performed on time
making them less effective.9-11 However,
when cultures of biological samples are per-
formed, results can take several days until
they become available. There is thus sub-
stantial room for improvement in this area.
For now, it is important that microbiological
diagnostics are performed before start of
therapy. For the near future more steps are
required to achieve the ideal situation of
available rapid diagnostics to minimize the
use of broad-spectrum empiric therapy. The
AMR Review calls upon the government of
the richest countries to achieve these goals
in 2020.2 It provides some steps to stimulate
new rapid diagnostics and how to finance
this, but not to improve current use of diag-
nostics. This is equally important in our
view, having diagnostics available is one
thing, but prescribers should also use them
correctly and interpret them correctly.6
Working together towards a solution
Not only are financial costs and benefits
of antimicrobial resistance and antimicro-
bial misuse divided from each other, but
also those of diagnostics and therapy (and
thus also of an ASP). This can lead to pre-
scribers (or departments) making the deci-
sion not to order diagnostics, because the
result will be available when the patient is
most likely already transferred to another
department. The benefits of these diagnos-
tics but also the consequences of not doing
diagnostics often fall therefore not on the
prescribers but on others. The question will
therefore be how to make sure that process
and result is supported by correct (financial)
incentives. 
It is thus important to view diagnostics,
therapy and AMR development as one sin-
gle decisional process. Within this process
all involved stakeholders need to work
together on an institutional level.
Subsequently, these institutions should
work together on a regional level and final-
ly countries should work together on a
worldwide level. Nowadays, people can
travel within one day across the globe, and
carry with them their microorganisms, mak-
ing spread of AMR far easier than before. It
is vital that this high interconnectivity that
exits is not forgotten in tackling AMR.8
Ideally costs and benefits are looked at
from a process-based point of view, includ-
ing all stakeholders. This is however not
realistic to implement in most countries. We
suggest therefore an easier to implement
solution: combining diagnostics and thera-
py into one single product. Although this
does not completely fix the abovemen-
tioned issues, it is a realistic and achievable
first step. It would assure that diagnostics
are not forgotten or lost due to unfounded
budget costs. The costs of these products
should fall on the institution and not just on
the prescribing department. The internal
and national cost structure for healthcare is
of influence here. Countries with a diagno-
sis-based payment system [e.g. with diag-
nosis related groups (DRGs)] can imple-
ment such a single product relatively easy.
A combination of therapy and diagnostics
partly solves the raised issue of divided cost
and benefits, thereby removing the financial
incentive not to order diagnostics.
Furthermore, if such a combined product is
part of a diagnosis, it is also easier for gov-
ernments to invest in, and subsidize more
costly rapid diagnostics (one of the key
aspects of the O’Neill report) without the
risk of hospitals performing too much diag-
nostics because they are subsidized. In the
end, this proposed package of antimicrobial
therapy and diagnostics should improve the
possibilities to optimize antimicrobial ther-
apy, reduce unnecessary broad spectrum
antibiotics, reduce toxicity and catheter-
related infections and finally reduce AMR
development because there are more com-
plete diagnostic results available at an earli-
er time point. The benefits of all these posi-
tive effects not only fall upon the institution
that treats the patients of on the whole
region in which a patient moves and eventu-
ally the whole nation and world. 
The role of Antimicrobial
Stewardship Programs
It is worthwhile to notice, that only per-
forming diagnostics is not enough, the inter-
pretation and the logistics are equally
important. This means that rapid diagnos-
tics only work, if the laboratory can com-
municate the results effectively to the
responsible physician. Interpretation of
diagnostic results and advice on therapy are
perfect examples of tasks that can be per-
formed under the umbrella of ASP.
However, this brings with it additional costs
that should also be paid by someone.
Because of the importance of an ASP from
a quality point-of-view and the fact that
there seem to be some highly effective
interventions that they can facilitate, we
would suggest to accommodate these costs
in the package price of therapy and diagnos-
tics. For the Netherlands for example, an
ASP is mandatory for all hospitals. Such an
obligation also asks for a way of financing.
The AMR Review suggests that govern-
ments should be actively involved in
financing actions towards preventing AMR,
because the costs of doing nothing ultimate-
ly also falls on society and thus on the gov-
ernment.2 A package price, funded or subsi-
dized by governments (depending on the
cost structure present in a country) is in line
with this viewpoint. We feel that a conse-
quence of such a package price should be
that some kind of control is implemented
nationally to ensure that hospitals indeed
perform diagnostics and have an active
ASP.
Conclusions
The process of AMR development is a
complex one, with many different stake-
holders involved. It is not always clear what
the exact role and effect is of each of these
actors. It is however clear that there is a
misbalance in actions and consequences on
a clinical level, but as importantly also on a
financial level. This misbalance can facili-
tate the misuse of antimicrobials including
the performance of diagnostics. We would
therefore suggest a new cost structure to
reimburse diagnostics and to dissolve the
misbalance and create a financial incentive
to perform better quality of care regarding
antimicrobial use. This should ultimately
positively affect the development of AMR.
Because of the wide impact of AMR, espe-
cially on an economical level, national gov-
ernment should act upon this and contribute
in the finances of new techniques and
improved quality of care. The introduction
of a package price for antimicrobial therapy
and diagnostics is a solution that can answer
these issues and should therefore be investi-
gated further.
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